Expand JAZZ Menu
JAZZ MENU

JAZZ Latest Press Releases

-- April 27, 2026 --

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA PRNewswire 7:45 AM

-- April 21, 2026 --

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 PRNewswire 4:15 PM
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca (lurbinectedin) PRNewswire 4:05 PM

-- April 9, 2026 --

Jazz Pharmaceuticals to Present Research on Epidiolex (cannabidiol) and Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting PRNewswire 7:45 AM

-- April 1, 2026 --

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference PRNewswire 4:15 PM

-- March 24, 2026 --

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education PRNewswire 1:50 PM

-- March 18, 2026 --

Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 PRNewswire 7:44 AM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 24, 2026 --

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance PRNewswire 4:05 PM

-- February 17, 2026 --

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PRNewswire 4:15 PM

-- February 10, 2026 --

Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 PRNewswire 4:15 PM

-- January 12, 2026 --

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer Globe Newswire 7:05 AM

-- January 8, 2026 --

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer PRNewswire 4:05 PM

-- January 6, 2026 --

Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit PRNewswire 1:33 PM

-- December 17, 2025 --

Jazz Pharmaceuticals to Participate in Upcoming Investor Events PRNewswire 4:15 PM

-- December 5, 2025 --

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting PRNewswire 9:00 AM

-- December 2, 2025 --

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium PRNewswire 4:05 PM
Market Data Delayed 15 Minutes